DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma
In conclusion, DNAM-1-based CARs may have the potential to treat PVR and nectin-2 expressing hematological and solid tumors.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Bone Cancers | Cancer | Cancer & Oncology | Ewing's Sarcoma | Hematology | Leukemia | Melanoma | Myeloma | Neuroblastoma | Neurology | Ovarian Cancer | Ovaries | Sarcomas | Skin Cancer | Study